FORTE BIOSCIENCES, INC. (FBRX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.99M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -90.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $9.99M | $-90.00M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $7.82M | $-76.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $6.26M | $-70.66M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $5.29M | $-53.44M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $4.60M | $-43.68M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $3.91M | $-44.92M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $3.10M | $-36.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $3.18M | $-35.63M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $3.16M | $-37.22M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $3.21M | $-33.44M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $3.28M | $-32.49M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $3.36M | $-31.04M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $3.50M | $-24.25M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $3.84M | $-18.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $4.01M | $-13.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | $4.39M | $-12.26M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $4.96M | $-16.53M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $4.77M | $-19.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $4.21M | $-21.49M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | $3.53M | $-22.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $2.43M | $-19.99M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $1.45M | $-49.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $956.00K | $-46.28M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $8.46M | $-100.80M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $8.08M | $-96.48M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $36.01M | (m) | $7.57M | $-53.34M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $45.30M | $36.00K | $8.06M | $-61.51M | (m) | 125830.56% | 22388.89% | (m) | (m) |
| 2019-09-30 | $53.32M | $36.00K | $8.15M | $-69.92M | (m) | 148116.67% | 22630.56% | (m) | (m) |
| 2019-06-30 | $52.29M | $18.04M | $8.02M | $-51.37M | (m) | 289.91% | 44.47% | (m) | (m) |
| 2019-03-31 | $53.08M | $18.04M | $7.35M | $-49.88M | (m) | 294.29% | 40.75% | (m) | (m) |
| 2018-12-31 | $51.08M | $18.04M | $6.87M | $-45.85M | (m) | 283.21% | 38.09% | (m) | (m) |
| 2018-09-30 | $43.76M | (m) | $6.50M | $-37.43M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $39.06M | (m) | $6.06M | $-48.60M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $32.92M | (m) | $5.44M | $-41.92M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $29.11M | (m) | $4.45M | $-37.63M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $27.22M | (m) | $1.32M | $-31.69M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $19.17M | (m) | $1.06M | $-22.95M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.